William Blair Weighs in on FibroGen, Inc.’s Q1 2025 Earnings (NASDAQ:FGEN)

FibroGen, Inc. (NASDAQ:FGEN) – Stock analysts at William Blair cut their Q1 2025 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, May 7th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.04. William Blair has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($1.09) per share.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The firm had revenue of $27.14 million during the quarter, compared to analyst estimates of $40.00 million.

FibroGen Stock Down 17.5 %

Shares of FibroGen stock opened at $1.13 on Thursday. The firm has a market cap of $112.41 million, a price-to-earnings ratio of -0.46 and a beta of 0.88. The business has a fifty day simple moving average of $1.68 and a 200-day simple moving average of $1.24. FibroGen has a fifty-two week low of $0.33 and a fifty-two week high of $19.47.

Insider Activity

In other news, CEO Thane Wettig acquired 50,000 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was acquired at an average price of $1.91 per share, for a total transaction of $95,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 470,178 shares in the company, valued at approximately $898,039.98. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.98% of the company’s stock.

Institutional Investors Weigh In On FibroGen

Several hedge funds have recently modified their holdings of the stock. Fox Run Management L.L.C. acquired a new position in FibroGen during the third quarter valued at $37,000. Accel Wealth Management acquired a new position in FibroGen during the first quarter valued at $103,000. Mackenzie Financial Corp raised its position in FibroGen by 112.6% during the third quarter. Mackenzie Financial Corp now owns 51,490 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 27,275 shares during the period. Quantbot Technologies LP acquired a new position in FibroGen during the third quarter valued at $45,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in FibroGen during the first quarter valued at $131,000. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.